Patient education results in better sustained virological response to anti-viral therapy in a high number of patients with chronic hepatitis C than conventional care

2018 ◽  
Vol 68 ◽  
pp. S366
Author(s):  
François Habersetzer ◽  
M. Doffoël ◽  
C. Frederic ◽  
F.D. Nino ◽  
L. Jean-Philippe ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Patient Education ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Conventional Care ◽  
Viral Therapy ◽  
Number Of Patients ◽  
Anti Viral Therapy

Response of Ns5a inhibitors resistant patients to Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy for chronic hepatitis c virus infection

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Ahmed A Moanes ◽  
Hesham H Radwan ◽  
Yasser O Abd El Rahman ◽  
Mostafa M Abd El Nabi
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Hcv Treatment ◽  
Number Of Patients ◽  
Chronic Hepatitis C Virus ◽  
Chronic Hcv

Abstract Background Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications. Aim of the work to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus. Patients and Methods An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment. Results all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12). Conclusion the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/Paritaprevir/Ritonavir)/Sofosbuvir/Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).

Interferon-free anti-viral therapy for chronic hepatitis C

2020 ◽  
pp. 16-21
Author(s):  
Gulnara Maratovna Zheenalieva ◽  
Altynay Kanatbekovna Kanatbekova ◽  
Myskal Mamaziyaevna Abdikerimova ◽  
Mamaziya Mansurovich Abdikerimov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Antiviral Effect ◽  
Source Of Infection ◽  
Polymerase Inhibitors ◽  
Viral Therapy ◽  
Anti Viral Therapy

The analysis of the interferon-free regimen of antiviral therapy in combination with the latest nucleotide polymerase inhibitors (ledipasvir/sofosbuvir for 12 weeks) provided high rates of sustained virological response among patients with chronic hepatitis C (CHC) infected with the "1B" genotype, both in previously untreated patients (100 %) and treated (94.1 %). The combination of drugs with direct antiviral effect, significantly reduces the risk of resistance, and liver fibrosis. The interferon-free regimen of antiviral therapy practically does not depend on the factors that determined the effectiveness of treatment with pegeled interferon and ribavirin, which made it possible to completely exclude interferons from the treatment regimen for hepatitis C and achieve a significant increase in the effectiveness of therapy. The use of direct antiviral drugs in CHC has reduced the duration of the course of therapy, increased the convenience of use, and expanded the indications for treatment of patients who previously had no chance. In addition, the achievement of a stable virological response contributes to the implementation of anti-epidemic measures, affecting the first link of the epidemic process — the source of infection.

Early prediction of sustained virological response at day 3 of treatment with albinterferon-α-2b in patients with genotype 2/3 chronic hepatitis C

2009 ◽  
Vol 29 (9) ◽  
pp. 1350-1355 ◽  
Author(s):  
Avidan U. Neumann ◽  
Vincent G. Bain ◽  
Eric M. Yoshida ◽  
Keyur Patel ◽  
Erik Pulkstenis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Early Prediction ◽  
Genotype 2

scholarly journals Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis

2011 ◽  
Vol 48 (3) ◽  
pp. 179-185
Author(s):  
Leonora De Zorzi Piccoli ◽  
Angelo Alves de Mattos ◽  
Gabriela Perdomo Coral ◽  
Ângelo Zambam de Mattos ◽  
Diogo Edele dos Santos
Keyword(s):  
Body Mass Index ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Liver Steatosis ◽  
Pegylated Interferon ◽  
Factors Associated ◽  
Systemic Arterial Hypertension

CONTEXT: Chronic hepatitis C as well as non-alcoholic fatty liver disease are recognized as the main cause of liver disease in Western countries. It is common to see the concomitance of the diseases and the influence of steatosis in the sustained virological response of patients with hepatitis C virus. OBJECTIVE: Assess the sustained virological response in chronic hepatitis C patients according to the presence of liver steatosis. METHODS: One hundred sixty patients with chronic hepatitis C were retrospectively evaluated. Demographic data such as gender, age, body mass index, presence of diabetes mellitus and systemic arterial hypertension, virus genotype and use of pegylated interferon were analyzed, as was the staging of fibrosis and the presence of steatosis at histology. RESULTS: Most patients were male (57.5%), with a mean age of 48 ± 9.7 years. The most frequent genotype observed was 3 (56.9%) and, in the histological evaluation, steatosis was observed in 65% of the patients (104/160). Sustained virological response in patients with steatosis occurred in 38.5%, and in 32.1% in patients without steatosis (P = 0.54). When we analyzed possible factors associated with the presence of steatosis, only body mass index and systemic arterial hypertension revealed a significant association. When the factors that influenced sustained virological response were evaluated in a logistic regression, genotype and use of pegylated interferon proved to be independent factors associated to the response. CONCLUSION: In the evaluated patients the presence of liver steatosis did not influence the sustained virological response of patients with chronic hepatitis C treated with interferon and ribavirin.

Sign in / Sign up

Export Citation Format

Share Document